The GPR120 as a novel predictive and diagnostic marker for preeclampsia in the first trimester.
Key Points
To determine the role of GPR120 as a biomarker for predicting and diagnosing preeclampsia in the first trimester.
Analyzed GPR120 expression in early pregnancy of patients with preeclampsia.
Developed a nomogram for predicting preeclampsia risk.
Suggested larger multicenter cohorts for validating findings.
GPR120 expression was significantly higher in early pregnancy for preeclampsia patients.
The nomogram demonstrated predictive capabilities for the development of preeclampsia.
Abstract
GPR120 expression is significantly increased in early pregnancy of PE patients. The nomogram exhibited predictive capability for PE development but needs larger, multicenter cohorts for validation.